Lansoprazole (Standard)
Lansoprazole (Standard) is the analytical standard of Lansoprazole. This product is intended for research and analytical applications. Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor).
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 98%
- No. CAS: 103577-45-3
- Fòrmula: C16H14F3N3O2S
- Peso molecular:369.36
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Pureza y Documentación
-
Help & FAQs
-
HY-13662
LansoprazoleProton Pump Inhibitor -
HY-B0656A
Rabeprazole sodiumPump Inhibitor -
HY-17507
PantoprazoleProton Pump Inhibitor -
HY-B0113
OmeprazoleH+,K+-ATPase Inhibitor -
HY-17023
Esomeprazole sodiumProton Pump Inhibitor -
HY-B0656
RabeprazolePump Inhibitor -
HY-108540
BCHLAT1 Inhibitor -
HY-B0572
Zinc PyrithioneAntimicrobial Agent -
HY-101664
IlaprazoleProton Pump Inhibitor -
HY-B1446
Esomeprazole magnesiumH+, K+-ATPase Inhibitor -
HY-17421
TenatoprazoleProton Pump Inhibitor -
HY-17022
Esomeprazole magnesium trihydrateH+, K+-ATPase Inhibitor
Product Information
Information
Aplicación
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
No. CAS 103577-45-3
-
Peso molecular 369.36
-
Fòrmula C16H14F3N3O2S
-
SMILES
O=S(C1=NC2=CC=CC=C2N1)CC3=NC=CC(OCC(F)(F)F)=C3C
-
Synonyms
AG-1749 (Standard)
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Kokufu, T., et al., Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol, 1995. 48(5): p. 391-5. [Content Brief]
[2]. Rupinder K Sodhi, et al. Defensive effect of lansoprazole in dementia of AD type in mice exposed to streptozotocin and cholesterol enriched diet. PLoS One. 2013 Jul 31;8(7):e70487. [Content Brief]
[3]. Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330. [Content Brief]
[4]. Jun Matsukawa, et al. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol. 2011 May 1;81(9):1145-51. [Content Brief]
[5]. Erdinc Naseri, et al. Proton pump inhibitors omeprazole and lansoprazole induce relaxation of isolated human arteries. Eur J Pharmacol. 2006 Feb 15;531(1-3):226-31. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Lansoprazole (Standard) Related Classifications
HY-13662R Related Classifications
Powered by Bioz